Glenmark Pharmaceuticals Monday said it has received final approval from the US health regulator for Sevelamer Hydrochloride tablets, used to control serum phosphorus in patients with chronic kidney disease on dialysis.
The approved product is a generic version of Genzyme Corporation’s Renagel tablets. “Glenmark Pharmaceuticals Inc, USA (Glenmark) has been granted final approval by the United States Food and Drug Administration (USFDA) for Sevelamer Hydrochloride tablets in the strengths of 400 mg and 800 mg,” the company said in a BSE filing.
The company’s stock was trading at ₹604.25, down 1.66 per cent, on BSE. (PTI)